Abstract
The Oropouche virus (OROV), historically endemic to the Amazon, has spread to nearly all Brazilian states in 2024, with Espírito Santo emerging as a significant transmission hotspot in the Atlantic Forest biome. We characterized the epidemiological factors driving OROV spread in non-endemic Southeast Brazil, analyzing environmental and agricultural conditions contributing to viral transmission. Samples from 29,000 suspected arbovirus-infected patients were tested by RT-qPCR for Dengue, Chikungunya, Zika, Mayaro, and Oropouche virus. Between March and June 2024, OROV cases in the state reached 339, demonstrating successful local transmission.
Spatial analysis revealed that most cases clustered in municipalities with tropical climates and intensive cacao, robusta coffee, coconut, and pepper cultivation. Phylogenetic analysis identified the Espírito Santo OROV strains as part of the 2022-2024 Amazonian lineage. The rapid spread of OROV outside the Amazon highlights its adaptive potential and public health threat, emphasizing the need for enhanced surveillance and targeted control measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by Fundação de Amparo à Pesquisa e Inovação do Espírito Santo - FAPES (ED and AR)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the University of Vila Velha, Espírito Santo - Brazil (Certificate of Ethical Appreciation Presentation: 84698324.7.0000.5064). The Committee waived the requirement for written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.